• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

T3期膀胱癌:放疗后采用挽救性而非选择性膀胱切除术。

T3 bladder cancer: salvage rather than elective cystectomy after radiotherapy.

作者信息

Hope-Stone H F, Oliver R T, England H R, Blandy J P

出版信息

Urology. 1984 Oct;24(4):315-20. doi: 10.1016/0090-4295(84)90199-7.

DOI:10.1016/0090-4295(84)90199-7
PMID:6435300
Abstract

Treatment of a series of 194 patients with T3 (B2/C) tumors by radical radiotherapy, 5,000 to 5,500 rad in four weeks, produced a five-year survival of 40 per cent. Patients whose tumor completely disappeared after treatment (N = 97) had a five-year survival of 69 per cent. These results raise doubts about the necessity of performing elective cystectomy in patients who achieve complete response after radiotherapy, though the significantly better survival of partial responders who underwent salvage cystectomy emphasizes the need for an active policy of cystectomy once failure to respond completely to radiotherapy has been established and a need for techniques to give early indication of nonresponse to radiotherapy.

摘要

对194例T3(B2/C)期肿瘤患者进行根治性放疗,四周内给予5000至5500拉德,五年生存率为40%。治疗后肿瘤完全消失的患者(N = 97)五年生存率为69%。这些结果引发了对放疗后完全缓解的患者进行选择性膀胱切除术必要性的质疑,尽管接受挽救性膀胱切除术的部分缓解者生存率显著更高,这强调了一旦确定对放疗未完全反应,就需要积极采取膀胱切除术政策,以及需要有技术来早期提示对放疗无反应。

相似文献

1
T3 bladder cancer: salvage rather than elective cystectomy after radiotherapy.T3期膀胱癌:放疗后采用挽救性而非选择性膀胱切除术。
Urology. 1984 Oct;24(4):315-20. doi: 10.1016/0090-4295(84)90199-7.
2
Radical radiotherapy and salvage cystectomy as the primary management of transitional cell carcinoma of the bladder. Results following the introduction of a CT planning technique.根治性放射治疗和挽救性膀胱切除术作为膀胱移行细胞癌的主要治疗方法。引入CT规划技术后的结果。
Clin Oncol (R Coll Radiol). 2002 Apr;14(2):141-7. doi: 10.1053/clon.2002.0055.
3
[Cancer of the bladder. Results of radiotherapy after partial cystectomy].[膀胱癌。膀胱部分切除术后放疗的结果]
Radiol Med. 1985 Jul-Aug;71(7-8):510-6.
4
Salvage cystectomy following failed definitive radiation therapy for transitional cell carcinoma of bladder.膀胱移行细胞癌根治性放疗失败后挽救性膀胱切除术
Urology. 1985 Dec;26(6):550-3. doi: 10.1016/0090-4295(85)90358-9.
5
Invasive bladder cancer. Should patients who respond to radiotherapy be treated by cystectomy?浸润性膀胱癌。对放疗有反应的患者是否应接受膀胱切除术治疗?
Br J Urol. 1987 Sep;60(3):248-51. doi: 10.1111/j.1464-410x.1987.tb05492.x.
6
Salvage cystectomy after radiation failure in patients with bladder carcinoma.
South Med J. 1977 Nov;70(11):1279-81. doi: 10.1097/00007611-197711000-00009.
7
Bladder preservation for localized muscle-invasive bladder cancer: the survival impact of local utilization rates of definitive radiotherapy.局部保留膀胱治疗局限性肌层浸润性膀胱癌:根治性放疗局部使用率对生存的影响。
Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):e197-204. doi: 10.1016/j.ijrobp.2011.12.038. Epub 2012 Mar 6.
8
[Invasive tumors of the bladder. A study of 56 cases treated at the Gustave-Roussy Institute by total cystectomy and radiotherapy].[膀胱浸润性肿瘤。古斯塔夫-鲁西研究所56例接受全膀胱切除术和放疗治疗的病例研究]
Ann Urol (Paris). 1989;23(3):205-11.
9
Morbidity after preoperative radiotherapy and cystectomy in patients with bladder cancer.
Scand J Urol Nephrol. 1997 Apr;31(2):149-53. doi: 10.3109/00365599709070321.
10
Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive (T2/T3) bladder cancer.
Br J Urol. 1988 Oct;62(4):343-6. doi: 10.1111/j.1464-410x.1988.tb04362.x.

引用本文的文献

1
Invasive bladder cancer--possible future treatment considerations.浸润性膀胱癌——未来可能的治疗考量
Urol Res. 1986;14(4):191-4. doi: 10.1007/BF00441112.
2
Survival with bladder cancer, evaluation of delay in treatment, type of surgeon, and modality of treatment.膀胱癌患者的生存率、治疗延迟评估、外科医生类型及治疗方式。
BMJ. 1991 Aug 24;303(6800):437-40. doi: 10.1136/bmj.303.6800.437.